Aurigene Oncology Ltd. recently provided details on the discovery and preclinical characterization of AUR-243, a novel CBL-B inhibitor with a distinct therapeutic profile and best-in-class potential compared to other inhibitors. AUR-243 was described as a structurally distinct, oral small molecule demonstrating excellent potency, functional activity and superior efficacy.
There is evidence that NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-driven mechanisms may drive both peripheral and hypothalamic inflammation in preclinical obesity. NLRP3 inflammasome activation has been tied to the pathogenesis of obesity-related metabolic syndrome and its progression.
Nkarta Therapeutics Inc. has recently presented data for their allogeneic CAR natural killer (NK) cell therapy, NKX-019, targeting CD19 for treating autoimmune disease through B-cell targeting.
Researchers at Triana Biomedicines Inc. presented the preclinical characterization of TRI-611, a CNS-penetrant molecular glue degrader targeting ALK in models of ALK fusion-positive non-small-cell lung cancer.
Researchers from Monte Rosa Therapeutics Inc. reported preclinical efficacy data on MRT-8102, a selective NEK7 molecular glue degrader, designed to treat inflammatory diseases.
Researchers from Macrogenics Inc. presented preclinical efficacy data on MGC-026, an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody (MGA017) targeting B7-H3, linked to a cytotoxic exatecan payload via a cleavable Val-Ala-PABC linker using Synaffix Glycoconnect technology.
Researchers from Chemdiv Inc. and Eilean Therapeutics LLC recently presented preclinical data on ZE77-0273, an AI-designed, reversible pan-EGFR inhibitor developed to address a key unmet need in the treatment of EGFR-mutant non-small-cell lung cancer.
Prospect Therapeutics Inc.’s PSTA-2413 is a newly developed oral pan-RAS inhibitor that demonstrates selectivity over wild-type KRAS, along with strong in vitro potency and in vivo antitumor efficacy.
Antibody-drug conjugates (ADCs) carrying topoisomerase I (TOP1) inhibitors, such as trastuzumab deruxtecan (T-DXd), have achieved notable clinical success in HER2-positive and HER2-low cancers, but their broader application is challenged by payload-related safety issues and emerging resistance.
RSS
